REGU09029 2023 ATMP Quality Systems and Regulatory Affairs
This module is taken by Level 9 students enrolled on the MSc. in ATMP Manufacturing.
It aims to provide students with the background of Advanced Therapy Medicinal Products (ATMP) and how they differ to traditional biopharmaceuticals. In addition, the students will get an overview of the EU and US regulations that apply to ATMPs.
Learning Outcomes
On completion of this module the learner will/should be able to;
Discuss the nature and production of ATMP products
Describe ATMP manufacturing challenges, current and developing technologies, and quality control / quality affairs
Evaluate the global regulatory framework for biotechnology derived products
Differentiate the applications of EU & US regulations for ATMP marketing authorisations
Critically analyse EudraLex Volume 4 part IV and Annex I
Teaching and Learning Strategies
A virtual learning environment (e.g. Moodle) will be used as a repository of educational resources and as a means of assessment. Self‑directed, student‑centred, independent learning is a core aspect through completion of module coursework. Some aspects of flipped learning, groupwork, case studies and other active learninG methodologies will be incorporated into the module.
Module Assessment Strategies
The assessment approach for this module will be 100% Continuous Assessment with a range of assessment methods employed including some of the following: project assignments, evidence based assignment / critiques /essays, case studies, oral presentations, viva’s etc.
Repeat Assessments
Repeat continuous assessment of the failed elements will be assigned as per the current Marks and Standards
Indicative Syllabus
Discuss the nature and production of ATMP products
- What are ATMPs in EU and US and Types of ATMPs (cell therapy, gene therapy, regenerative medicine)
- History of ATMP development
- Drug development and clinical trials
- Roles and responsibilities
Describe ATMP manufacturing challenges, current and developing technologies, and quality control / quality affairs.
- Key considerations for the manufacture and testing of ATMPs
- Product lifecycle and product approval pathway in the EU and US
Demonstrate an understanding of the global regulatory framework for biotechnology derived products
- EU guidance documents (EudraLex)
- US ATMP guidance documents (FDA website)
- ICH guidelines with a focus on ICH Q8, Q9, Q10, and Q11.
Differentiate the applications of EU & US regulations for ATMP marketing authorisations
- Expedited Regulatory pathways for ATMPs in the EU and US
- Accelerated pathways and orphan drug designation
Critically analyse EudraLex Volume 4 part IV and Annex I
- Overview of EudraLex Volume 4 Annex I and how it applies to ATMP
- Overview of EudraLex Volume 4 part IV for ATMPs
Coursework & Assessment Breakdown
Coursework Assessment
Title | Type | Form | Percent | Week | Learning Outcomes Assessed | |
---|---|---|---|---|---|---|
1 | Assignment | Coursework Assessment | Assignment | 20 % | Week 4 | 1,2 |
2 | Case study | Coursework Assessment | Assignment | 30 % | Week 11 | 3 |
3 | Project and presentation | Coursework Assessment | Individual Project | 50 % | End of Semester | 4,5 |
Online Learning Mode Workload
Type | Location | Description | Hours | Frequency | Avg Workload |
---|---|---|---|---|---|
Lecture | Online | Lecture | 2 | Weekly | 2.00 |
Required & Recommended Book List
2015-09-25 Regulatory Aspects of Gene Therapy and Cell Therapy Products Springer
ISBN 3319186175 ISBN-13 9783319186177
This book discusses the different regulatory pathways for gene therapy (GT) and cell therapy (CT) medicinal products implemented by national and international bodies throughout the world (e.g. North and South America, Europe, and Asia). Each chapter, authored by experts from various regulatory bodies throughout the international community, walks the reader through the applications of nonclinical research to translational clinical research to licensure for these innovative products. More specifically, each chapter offers insights into fundamental considerations that are essential for developers of CT and GT products, in the areas of product manufacturing, pharmacology and toxicology, and clinical trial design, as well as pertinent "must-know" guidelines and regulations. Regulatory Aspects of Gene Therapy and Cell Therapy Products: A Global Perspective is part of the American Society of Gene and Cell Therapy sub-series of the highly successful Advances in Experimental Medicine and Biology series. It is essential reading for graduate students, clinicians, and researchers interested in gene and cell therapy and the regulation of pharmaceuticals.
2020-06-27 A Handbook of Gene and Cell Therapy Springer Nature
ISBN 9783030413330 ISBN-13 3030413330
This is a reference handbook for young researchers exploring gene and cell therapy. Gene therapy could be defined as a set of strategies modifying gene expression or correcting mutant/defective genes through the administration of DNA (or RNA) to cells, in order to treat disease. Important advances like the discovery of RNA interference, the completion of the Human Genome project or the development of induced pluripotent stem cells (iPSc) and the basics of gene therapy are covered. This is a great book for students, teachers, biomedical researchers delving into gene/cell therapy or researchers borrowing skills from this scientific field.
Module Resources
- Eudralex Volume 4 Part IV: https://health.ec.europa.eu/system/files/2017-11/2017_11_22_guidelines_gmp_for_atmps_0.pdf
- Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. Guidance for Industry and Food and Drug Administration Staff. JULY 2020. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal
-
REGULATION (EC) No 1394/2007 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004